(Q40450413)

English

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

scientific article published on 21 January 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

Ruth Knüchel-Clarke

3

object named as

Ruth Knuechel-Clarke

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

6

object named as

Gero Brockhoff

0 references

author name string

Simone Diermeier

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gábor Horváth

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ferdinand Hofstaedter

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

János Szöllosi

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gero Brockhoff

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

21 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Experimental Cell Research

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

304

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

604-619

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Evaluating HER2 amplification and overexpression in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Antibodies as molecular target-based therapy: trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Biology of HER2 and its importance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The role of ubiquitylation in signaling by growth factors: implications to cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

A new therapeutic antibody masks ErbB2 to its partners

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Signal transduction and oncogenesis by ErbB/HER receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.12.008

7 January 2021

Identifiers

10.1016/J.YEXCR.2004.12.008

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40450413&oldid=2206872636"